StockNews.com Initiates Coverage on Moleculin Biotech (NASDAQ:MBRX)

Stock analysts at StockNews.com started coverage on shares of Moleculin Biotech (NASDAQ:MBRX) in a research report issued to clients and investors on Monday. The firm set a “sell” rating on the stock.

Several other brokerages have also commented on MBRX. Roth Mkm reaffirmed a “buy” rating and set a $40.00 price target on shares of Moleculin Biotech in a research report on Friday, April 12th. Maxim Group dropped their price target on shares of Moleculin Biotech from $45.00 to $20.00 and set a “buy” rating for the company in a research report on Tuesday, March 26th.

Moleculin Biotech Price Performance

NASDAQ:MBRX opened at $4.63 on Monday. The firm has a 50 day simple moving average of $6.69 and a 200-day simple moving average of $8.03. The firm has a market cap of $10.32 million, a PE ratio of -0.34 and a beta of 1.95. Moleculin Biotech has a 1-year low of $4.28 and a 1-year high of $15.75.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Moleculin Biotech stock. Atticus Wealth Management LLC purchased a new position in Moleculin Biotech, Inc. (NASDAQ:MBRX) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 50,001 shares of the company’s stock, valued at approximately $43,000. Atticus Wealth Management LLC owned about 0.17% of Moleculin Biotech as of its most recent filing with the Securities and Exchange Commission. 15.52% of the stock is owned by institutional investors.

About Moleculin Biotech

Moleculin Biotech, Inc, a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs.